This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.
Join leading expert Dr. Ralph Audehm for this virtual session exploring the primary care management of obesity treatment plateaus and non-response. Utilizing interactive clinical cases, this expert-led webinar equips healthcare providers with evidence-based strategies to evaluate treatment efficacy, navigate complex therapeutic plateaus during anti-obesity medication therapy, and proactively manage side effects through patient-centric monitoring.
Participants will explore actionable pathways to address clinical hesitation and evaluate patients who fail to reach standard weight-loss targets, such as a 5% reduction at the 12-week or 16-week mark. By reviewing factors like dose optimization, medication adherence, and lifestyle support, practitioners will learn to collaboratively adjust treatment plans rather than prematurely abandoning therapy. Furthermore, the session emphasizes the chronic nature of obesity, providing structured guidance on transitioning patients through therapeutic plateaus while preserving body composition and maximizing long-term health benefits.
This is Module Three of Four. Modules One and Two and Four can be found here.
Prefer to read? see our Key Clinical Summary Here
Session Highlights
- Evaluating Treatment Efficacy and Plateaus: Master structured reassessment algorithms to determine true therapeutic non-response versus a physiological weight plateau early in anti-obesity therapy.
- Overcoming Adherence Barriers: Gain tactical insights into identifying and addressing the root causes of sub-therapeutic dosing and medication non-adherence, including delayed dose escalation due to patient anxiety or missed doses.
- Patient-Centric Side-Effect Mitigation: Implement proactive protocols to monitor, counsel, and manage common GLP-1RA adverse events—such as nausea, vomiting, diarrhea, and lightheadedness—to prevent premature treatment discontinuation.
- Long-Term Goal Setting and Adaptation: Formulate proactive, long-term adherence pathways through shared decision-making, setting personalized, realistic weight loss targets, and executing timely treatment adjustments, combination therapies, or specialist referrals.
Who Should Watch
This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.
Faculty
Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Continuing Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number -JA4008073-9999-26-294-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.
Estimated time to complete this activity: 15 Minutes